cyproterone acetate / Generic mfg. - LARVOL DELTA

Long-Term Effects of Gender-Affirming Hormone Therapy from Adolescence to Adulthood on Voice. (PubMed, J Voice) - "Voice masculinization in transgender men who initiate GAHT during adolescence typically results in vocal characteristics comparable to those of cisgender men. In transgender women, earlier GHS may help preserve a more feminine voice, but complete alignment with cisgender women is not guaranteed (if this is the goal), especially in reading and spontaneous speech. These findings underscore the importance of early pubertal intervention and access to individualized voice care, including speech-language pathology support for trans persons."

Journal • Dysphonia • Otorhinolaryngology

Changes in temperature perception in transgender persons undergoing gender-affirming hormone therapy. (PubMed, Commun Med (Lond)) - P | "We demonstrate that in trans women undergoing GAHT with estradiol and cyproterone acetate sensitivity to temperature changes increases, consistent with the greater temperature sensitivity observed in cis women compared to cis men. Future studies need to assess at which neurobiological processing stages the relevant changes occur and what molecular mechanisms play a role."

Journal • Pain

Male Rat Model of Chemical Androgen Deprivation and Estrogenization from the Perspective of Anthropometric, Histological, and Biochemical Parameters. (PubMed, Medicina (Kaunas)) - "Materials and Young adult Wistar rats were divided into nine groups: intact control (IC), control vehicle (CV), cyproterone acetate-treated (CA), flutamide-treated (F), control sesame oil (CO), estradiol valerate-treated (E), combined control (CC), flutamide + estradiol valerate (F + E), and cyproterone acetate + estradiol valerate (CA + E)-treated groups. Regarding biochemical parameters, androgen deprivation and/or estrogenization caused marked changes in serum triglyceride, LDL (low-density lipoproteins), ALP (alkaline phosphatase), AST (aspartate aminotransferase), ALT (alanine aminotransferase), Bil-T (bilirubin), creatinine, and urea levels. Given the importance of these therapies in clinical practice, providing a model based on the evaluated parameters offers a solid platform for future research."

Journal • Preclinical • Dyslipidemia • Fibrosis • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

MESURE: MEdical Versus SUrgical Treatments of Rectal Endometriosis (clinicaltrials.gov) - P3 | N=78 | Completed | Sponsor: University Hospital, Rouen | Unknown status ➔ Completed

Trial completion • Endometriosis • Gynecology • Women's Health

Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review. (PubMed, Clin Cosmet Investig Dermatol) - "Eligible articles included randomized controlled trials, cohort studies, systematic reviews, and meta-analyses evaluating hormonal therapies such as combined oral contraceptives (COCs), spironolactone, cyproterone acetate, and topical antiandrogens (eg, clascoterone)...Hormonal therapies are effective and well-tolerated options for acne, particularly in women with hormonal patterns or refractory disease. By specifically targeting androgen-driven pathways, hormonal agents offer sustained improvement and should be incorporated into personalized acne management."

Journal • Review • Acne Vulgaris • Dermatology • Inflammation

MRI-PCOS: Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - P=N/A | N=52 | Completed | Sponsor: University Hospital, Lille | Active, not recruiting ➔ Completed

Trial completion • Polycystic Ovary Syndrome

Impact of Growth-promoting Therapies on Puberty, Growth, and Final Height in Classical 21-hydroxylase Deficiency. (PubMed, J Clin Endocrinol Metab) - "Patients with 21-OHD had diminished FH despite early diagnosis. Puberty in classical 21-OHD had an earlier onset, slower tempo, and prolonged duration, especially in girls, in which GPTs are less effective in promoting height. The management of pubertal growth needs a personalized approach in patients with classical 21-OHD."

Journal • Congenital Adrenal Hyperplasia • Endocrine Disorders

Connection between granulosa cell pyroptosis and oocyte endoplasmic reticulum stress in a mouse model of polycystic ovary syndrome. (PubMed, J Ovarian Res) - "High androgen induced pyroptosis of ovarian granulosa cells in a mouse model of PCOS, leading to ER stress in oocytes and a decrease of the oocyte maturation rate. Effective alleviation of granulosa cell pyroptosis can inhibit ER stress in oocytes and improve their maturation rate. This study provides new therapeutic targets for improving oocyte maturation in PCOS."

Journal • Preclinical • Polycystic Ovary Syndrome • CASP1

Cyproterone acetate for hirsutism. (PubMed, Cochrane Database Syst Rev) - "There were some differences in clinical outcome between CPA and spironolactone, CPA and flutamide, and CPA and finasteride. There were no clinical differences between CPA and the other medical therapies, possibly because of small study size, lack of standardised assessment and objective determinants of improvement in many studies. There are insufficient data presented to compare the adverse effects of all the treatment options. Larger, carefully designed studies are needed to compare efficacy and safety profiles between the therapeutic options available."

Clinical • Journal • Review • Gynecology

Off-target molecular recognition of cyproterone acetate by human lysozyme: conformational remodelling, enzyme modulation, and amyloid inhibition. (PubMed, Bioorg Chem) - "Collectively, these findings establish CPA as an off-target modulator of protein structure, activity, and aggregation, extending its pharmacological profile beyond androgen receptor antagonism. The dual effects of enzymatic activation and amyloid suppression highlight the potential of steroidal scaffolds as anti-amyloid agents, with broader implications for protein misfolding disorders."

Journal • Proteinopathy

Impact of terminal groups on PLGA degradation rate and their role in sustained release of cyproterone acetate. (PubMed, Eur J Pharm Biopharm) - "The insights gained from this study will enhance the understanding of PLGA degradation and the mechanisms underlying the release of loaded actives from PLGA microspheres. Furthermore, the modification of terminal groups has the potential to support the development of advanced pharmaceutical excipients."

Journal

Identifying Risk Factors Associated With Meningioma: A Systematic Review (ISPOR-EU 2025) - "Hormonal exposures including chlormadinone acetate (RR = 3.1), cyproterone acetate (RR = 11.4) and fertility treatments (OR = 4.97) were significantly increased risk. Meningioma risk is influenced by age, gender, BMI, height, hormonal therapies, analgesics, and occupational exposure to metals and radiation, highlighting the complex interplay of biological, environmental, and lifestyle factors."

Clinical • Review • Brain Cancer • Genetic Disorders • Meningioma • Obesity • Solid Tumor

Delayed regression of atypical meningiomatosis following discontinuation of gender-affirming hormone therapy in a transgender woman: a case report. (PubMed, Br J Neurosurg) - "Cyproterone acetate (CPA) is an antiandrogen that may be used in combination with estradiol in gender reaffirmation therapy...However, its effect appears to be delayed, indicating that cessation alone is suboptimal in cases causing significant mass effect and symptomatology. In such cases, early surgical intervention should be considered."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor • PGR

Impact of gender-affirming hormone therapy on spermatogenesis: analysis of testicular histological specimens. (PubMed, Hum Reprod) - "These findings provide clinically relevant insights for fertility counseling in TGD individuals, emphasizing that CPA and progesterone significantly impair spermatogenesis, whereas spironolactone may allow for greater preservation of sperm maturation. This has implications for fertility preservation discussions prior to GAHT initiation and may inform individualized hormone regimen selection based on reproductive goals."

Journal

Carboxyl-PEG modified Fe3O4 nanoparticles as an ultrasensitive SERS substrate for multiplex detection of exogenous hormones related to endometrial cancer. (PubMed, Methods) - "This approach successfully enabled ultrasensitive detection and precise discrimination of multiple typical exogenous hormonal drugs, including tamoxifen, drospirenone, cyproterone acetate, medroxyprogesterone acetate, estradiol ester derivatives, and dydrogesterone. In matrix-spiked serum and urine samples, which mimic complex biological matrices validations, the AI-SERS platform demonstrated exceptional performance in the identification and quantitative analysis of target exogenous hormones. This research provides an intelligent analytical strategy for rapid and highly sensitive detection of multiple trace exogenous hormones in complex matrices."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Plasma proteome adaptations during feminizing gender-affirming hormone therapy. (PubMed, Nat Med) - "Here we examined plasma proteome changes over 6 months of feminizing GAHT in 40 transgender individuals treated with estradiol plus one of two antiandrogens: cyproterone acetate or spironolactone. Feminizing GAHT skewed the protein profile toward that linked to asthma and autoimmunity, while GAHT with cyproterone specifically skewed it away from an atherosclerosis-associated profile, suggesting a protective effect. These results reveal that feminizing GAHT reshapes the plasma proteome in a hormone-dependent manner, with implications for reproductive capacity, immune regulation and long-term health outcomes."

Journal • Asthma • Atherosclerosis • Cardiovascular • Immunology • Pulmonary Disease • Respiratory Diseases • CXCL13 • LEP • NOS3

THE NAPCSR, THE BIOMARKER FOR CHC-ASSOCIATED THROMBOTIC RISK EVALUATION (FIGO 2025) - " nAPCsr was assessed on plasma samples from women using either no contraception (n = 220), progestin-only pill (POP) (n = 14), natural estrogen (estradiol or estetrol)-based CHC (n = 43), ethinylestradiol (EE) 20 or 30 μg with levonorgestrel (n = 70), EE 20 μg with desogestrel, gestodene or drospirenone (n = 105) and EE ≥30 μg with desogestrel, dienogest or cyproterone acetate (n = 32). For non-users or women using POP, nAPCsr >3.0 indicate a procoagulable state, which could be attributable to thrombophilia (e.g. FV Leiden), meaning the pill should be contraindicated. For women already on CHCs, nAPCsr above respective thresholds indicate that the benefit–risk balance of the contraceptive formulation used is questionable."

Biomarker • Hematological Disorders • Hepatitis C

Polycystic ovary syndrome and estroprogestins. (PubMed, Minerva Obstet Gynecol) - "In conclusion, an aware choice of the most adequate and tolerable EP formulation according to the pharmacological profile and individual characteristics of PCOS patient is essential to opportunely customize the treatment of androgen excess."

Journal • Acne Vulgaris • Alopecia • Genetic Disorders • Immunology • Obesity • Polycystic Ovary Syndrome • Seborrheic Dermatitis • Women's Health

Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Medical University of Vienna | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial primary completion date • CNS Disorders

Immunohistochemical evaluation of testicular tissue from gender-incongruent individuals after gender-affirming hormone therapy (DGU 2025) - "Treatments included cyproterone acetate (CPA) and estrogens (68%), estrogens (13%), spironolactone and estrogens (6%), estrogens and GnRH analogues (3%), or CPA (0.5%) and progesterone (0.2%). Most patients had impaired spermatogenesis. The incidence of GCNIS tended to be higher in transgender individuals in this cohort compared to those without hormone therapy. These findings may improve the counseling provided by treating physicians."

Clinical • Germ Cell Tumors • ALPP

CV-TGD: Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway (clinicaltrials.gov) - P=N/A | N=500 | Recruiting | Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

New trial • Cardiovascular

Androgenetic alopecia in the transgender population: experience in a public hospital in Latin America (EADV 2025) - "Among TW, 75% (3/4) were on hormone therapy with varying regimens of estrogens, cyproterone, and spironolactone...The NB patient received topical 5% minoxidil without hormone therapy...Finasteride and dutasteride are safe options for both groups; dutasteride is preferred after finasteride failure... AGA is a common finding in TM and NB individuals on testosterone, typically developing 2–5 years after hormone initiation. In TW, hormone therapy may slow the progression of androgenetic alopecia; however, hair regrowth is uncommon, and specific therapeutic interventions are often required. Most therapeutic strategies are based on cisgender guidelines due to limited trans-specific research."

Clinical • Alopecia • Immunology

A series of 510 cases of hypertrichosis in women: Epidemioclinical profile, proposed treatments, and psychosocial repercussions (EADV 2025) - "Furthermore, 5.9% of the women had received medical treatment for hypertrichosis, with anti-androgens such as cyproterone acetate being the most prescribed (69.5%)... Our findings indicate a high prevalence of hypertrichosis among young women, a result that is not surprising and aligns with existing literature, particularly for those with hormonal disorders such as acne and PCOS. Current treatment options, do not always yield satisfactory results for all patients, necessitating a more personalized and multidisciplinary approach. Hair removal methods remain the most commonly used solutions, but their perceived effectiveness is limited."

Clinical • Acne Vulgaris • Aesthetic Medicine • CNS Disorders • Dermatology • Polycystic Ovary Syndrome

Volumetric courses of the intraosseous and meningeal components of osteomeningiomas after cyproterone acetate treatment withdrawal. (PubMed, J Neurosurg) - "While the meningeal and intraosseous components of OMs respond differently to CPA withdrawal, their growth dynamics remain correlated."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor

Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial. (PubMed, Ther Adv Endocrinol Metab) - P4 | "Women with PCOS and AO who fulfilled the Rotterdam Criteria under combined treatment with daily cyclical ethinylestradiol (35 μg/day) and cyproterone acetate (2 mg/day). Network pharmacology identified genes related to AO and metabolism in patients with PCOS under the metformin-exenatide treatment. ClinicalTrials.gov NCT04029272."

Clinical • Journal • Genetic Disorders • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome • APOA1